mTOR inhibitors clinical trials
A class of medicines: the studies that test any of its 3 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: MTOR Inhibitors.
Get an email when these change. Save the mtor inhibitors studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
1,265 studies that test it; most in 2009 (121); 3 more planned to start later
| Year | Studies |
|---|---|
| 1996 | 2 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 11 |
| 2001 | 13 |
| 2002 | 21 |
| 2003 | 15 |
| 2004 | 42 |
| 2005 | 56 |
| 2006 | 72 |
| 2007 | 71 |
| 2008 | 98 |
| 2009 | 121 |
| 2010 | 118 |
| 2011 | 82 |
| 2012 | 79 |
| 2013 | 52 |
| 2014 | 57 |
| 2015 | 44 |
| 2016 | 38 |
| 2017 | 38 |
| 2018 | 31 |
| 2019 | 21 |
| 2020 | 24 |
| 2021 | 23 |
| 2022 | 26 |
| 2023 | 18 |
| 2024 | 29 |
| 2025 | 29 |
| 2026 | 32 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 211 · Other 1,065
Novartis Pharmaceuticals (112) · National Cancer Institute (NCI) (68) · M.D. Anderson Cancer Center (49) · Wyeth is now a wholly owned subsidiary of Pfizer (28) · Dana-Farber Cancer Institute (25) · National Institute of Allergy and Infectious Diseases (NIAID) (23) · Mayo Clinic (21) · Emory University (18)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 1,276
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Sirolimus
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingPhase 1/2Umoja BiopharmaNCT07735533Written as Rapamycin (sirolimus)
- A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.Not yet recruitingEarly Phase 1Northwestern UniversityNCT07813533Written as sirolimus topical gel 0.2%
- Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsRecruitingPhase 1/2Astellas Gene TherapiesNCT07052929Written as Sirolimus
- Expanding Liver Transplant Immunosuppression Minimization Via EverolimusRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06280950Written as Everolimus
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as Sirolimus
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518Written as Everolimus
- Rapamycin Dose-Ranging Efficacy Study in Port Wine StainsNot yet recruitingPhase 2AFT Pharmaceuticals, Ltd.NCT07436611Written as Rapamycin cream
- Advancing Transplantation Outcomes in ChildrenRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06055608Written as Sirolimus
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated RejectionRecruitingNot applicableHospices Civils de LyonNCT03955172Written as Everolimus
- Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsRecruitingPhase 2/3Katarzyna KotulskaNCT04987463Written as Rapamycin
- Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingPhase 2ANRS, Emerging Infectious DiseasesNCT07081763Written as Sirolimus 2 MG
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965Written as Everolimus
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingPhase 1Umoja BiopharmaNCT06528301Written as rapamycin
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839Written as Sirolimus
- Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet DisorderRecruitingPhase 1OHSU Knight Cancer InstituteNCT07844694Written as Sirolimus
- Effects of Sirolimus on Asymptomatic ApoE4 CarriersRecruitingPhase 1University of Missouri-ColumbiaNCT07728175Written as Sirolimus (rapamycin)
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingPhase 3Hannover Medical SchoolNCT07739914Written as Everolimus
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingPhase 1/2University Hospital, Strasbourg, FranceNCT07853105Written as Dinutuximab beta, Sirolimus and Irinotecan
- Sirolimus Discontinuation Strategies in Kaposiform HemangioendotheliomaRecruitingPhase 2West China HospitalNCT07131644Written as Sirolimus
See all 1,276 studies that test one of the mtor inhibitors →